Alison Moskowitz

9PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 26, 2026
Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.

|Dec 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Pallawi Torka, Tatyana Feldman, Kerry J Savage

|Feb 02, 2024
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).

Alison J Moskowitz, Robert N Stuver, Steven M Horwitz

|Sep 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.

Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder

|Jun 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Alison J Moskowitz, Gunjan Shah, Heiko Schöder

|Apr 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.

Anita Kumar, Carla Casulo, Ranjana H Advani

Pageof 2

Frequent Collaborators

5 joint publications

Steven M Horwitz

4 joint publications

Andrew D Zelenetz

4 joint publications

Heiko Schöder

4 joint publications

Maria Lia Palomba